2020 Fiscal Year Final Research Report
Elucidation and overcoming of immune checkpoint inhibitor resistance mechanism in non-small cell lung cancer
Project/Area Number |
19K18222
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 55040:Respiratory surgery-related
|
Research Institution | Fukushima Medical University |
Principal Investigator |
Muto Satoshi 福島県立医科大学, 医学部, 助教 (90722570)
|
Project Period (FY) |
2019-04-01 – 2021-03-31
|
Keywords | がん免疫 / 免疫療法 / 免疫チェックポイント阻害薬 / 薬剤耐性 |
Outline of Final Research Achievements |
We investigated immune escape mechanisms other than immune checkpoints, which were considered as candidates for resistance mechanisms of immune checkpoint inhibitors, in non-small cell lung cancer. As a result, activation of the Wnt / β-catenin pathway occurred relatively frequently in non-small cell lung cancer. We analyzed and reported on the mechanism by which activation of the Wnt / β-catenin pathway causes immune escape in non-small cell lung cancer, focusing on antigen-presenting cells.
|
Free Research Field |
呼吸器外科
|
Academic Significance and Societal Importance of the Research Achievements |
非小細胞肺癌における免疫チェックポイント阻害薬の耐性メカニズムとして、Wnt/β-catenin経路の活性化が重要であることを明らかにした。今後Wnt/β-catenin経路を阻害する薬剤を併用するなど、今回明らかとなった耐性メカニズムを解除することで、免疫チェックポイント阻害薬の治療効果を高めることが期待される。これにより新たな治療法の開発に発展する可能性が示唆される。
|